At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 269 enrolled
Drug / intervention
13-valent Pneumococcal Conjugate Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomised,Active-Controlled ,Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Manufacturing Scale 13-valent Pneumococcal Conjugate Vaccine
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Apr 24, 2007·Updated Aug 15, 2012
In Brief
A Phase 3 clinical trial evaluating 13-valent Pneumococcal Conjugate Vaccine for Pneumococcal Vaccines. Completed, enrolled 269 participants across 9 sites.
Detailed Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate (13vPnC) vaccine compared to pilot scale 13vPnC in healthy infants when given with routine pediatric vaccines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Vaccines
CountriesPoland
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartJun 2007
Primary CompletionSep 2008
TodayJul 2026
First PostedApr 24, 2007
Enrollment StartJun 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.2 years ago
Interventions
13-valent Pneumococcal Conjugate Vaccinebiological
1 dose at 2,3,4 and 12 months of age